InvestorsHub Logo
Followers 12
Posts 1186
Boards Moderated 0
Alias Born 05/21/2013

Re: xray168 post# 118

Tuesday, 08/25/2020 12:59:03 AM

Tuesday, August 25, 2020 12:59:03 AM

Post# of 190
Kedrion is currently collecting COVID-19 convalescent plasma from U.S. recovered patients that will be used by Kamada to manufacture additional batches of the product.

This global collaboration expands the existing relationship between Kamada and Kedrion beyond KEDRAB®, a plasma-derived FDA-approved human rabies immunoglobulin that was launched successfully in the U.S. during 2018.

Partnership with Kedrion Biopharma
Kamada and Kedrion Biopharma, a global leader in plasma collection and plasma-derived therapeutics, announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived immune-globulin for Coronavirus. as a potential treatment for COVID-19 patients.

https://www.kamada.com/therapeutic_areas/covid-19/?fbclid=IwAR0Quimguoc5_oFGKEw_EPVEzha5c79Eh7YMs9iK6f5sN8R-SnjEdS6zz_0
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMDA News